People with Dupuytren’s contracture will now be able to avoid surgery to correct the condition.
The condition causes fingers to pull permanently towards the palm and makes everyday tasks, such as dressing and washing, very difficult. Sufferers are also likely to suffer wider psychological effects.
Dupuytren’s contracture is commonly treated with surgery, but this has been linked to post-operative complications, high rates of recurrence and disruption to patients’ lives.
Pfizer has developed Xiapex, which is the first injection available to treat the condition. Just 24 hours after the injection, a procedure can be carried out to help straighten the patient’s finger.
Jonathan Jones, medical director of Pfizer’s Speciality Care Business Unit, said: “The development and availability of a new treatment like Xiapex for Dupuytren’s contracture demonstrates Pfizer’s continued commitment to bring new innovative medicines to patients and is good news for patients and physicians alike.”
Sign our petition today to ensure nurses have a seat on consortia boards! Follow @Aseatontheboard on twitter follow for all the latest campaign news!